

---

# Advances in **CANCER RESEARCH**

---

**Volume 80**

Edited by

**George F. Vande Woude**

*Division of Basic Sciences  
National Cancer Institute  
National Institutes of Health  
Bethesda, Maryland*

**George Klein**

*Microbiology and Tumor Biology Center  
Karolinska Institutet  
Stockholm, Sweden*



**ACADEMIC PRESS**

A Harcourt Science and Technology Company

*San Diego San Francisco New York Boston London Sydney Tokyo*

Contributors to Volume 80 ix

## **Involvement of Platelet-Derived Growth Factor in Disease: Development of Specific Antagonists**

Arne Östman and Carl-Henrik Heldin

- I. Introduction 2
- II. Platelet-Derived Growth Factor (PDGF) and PDGF Receptors 3
- III. Intracellular Signal Transduction 5
- IV. *In Vivo* Function of PDGF 9
- V. PDGF in Disease 13
- VI. PDGF and PDGF Receptors as Drug Targets 19
- VII. Future Perspectives 27
- References 28

## **Tumor Suppression Activity of Adenovirus E1a Protein: Anoikis and the Epithelial Phenotype**

Steven M. Frisch

- I. Introduction 39
- II. Historical Development of E1a as a Tumor Suppressor 40
- III. Epithelial Conversion: Phenomenology 41
- IV. Epithelial Conversion: Mechanisms 41
- V. Anoikis Sensitization and Tumor Suppression by E1a 44
- References 46

## **Comparative Analysis of the Transforming Mechanisms of Epstein-Barr Virus, Kaposi's Sarcoma-Associated Herpesvirus, and Herpesvirus Saimiri**

Blossom Damania and Jae U. Jung

- I. Introduction 51

- II. Comparative Analysis of Gamma Herpesvirus Gene Products 55
- III. Conclusion 73
- References 74

## **Genetic Predisposition and Somatic Diversification in Tumor Development and Progression**

Darryl Shibata and Lauri A. Aaltonen

- I. Introduction 84
- II. Hereditary Colorectal Cancer Syndromes 85
- III. Tumor Mutations and Molecular Clocks: Gateways to the Fourth Dimension 89
- References 110

## **Primary Effusion Lymphoma: A Liquid Phase Lymphoma of Fluid-Filled Body Cavities**

Gianluca Gaidano and Antonino Carbone

- I. Definition of Primary Effusion Lymphoma 116
- II. Histogenes of Primary Effusion Lymphoma 119
- III. Pathogenesis of Primary Effusion Lymphoma 121
- IV. Epidemiology of Primary Effusion Lymphoma 133
- V. Clinical Features of Primary Effusion Lymphoma 135
- VI. Radioimaging of Primary Effusion Lymphoma 136
- VII. Differential Diagnosis of Primary Effusion Lymphoma 136
- VIII. Therapy of Primary Effusion Lymphoma 137
- IX. Perspectives 138
- References 140

## **Dimensions of Antigen Recognition and Levels of Immunological Specificity**

Neil S. Greenspan

- I. Introduction 148
- II. Logical Preliminaries: Boundaries of Categories and Categories  
of Boundaries 149
- III. Monovalent Recognition 153
- IV. Multivalent Recognition 165
- V. Specificity of Cellular Activation 171
- VI. Organismal Specificity 174
- VII. Conclusions 182
- References 183

## **Topoisomerase I-Mediated DNA Damage**

Philippe Pourquier and Yves Pommier

- I. Introduction 189
- II. Structural Domains of Top1 190
- III. Top1 Functions and Protein Interactions 191
- IV. The Top1 Catalytic Cycle and Cleavage Complexes 195
- V. Anticancer Top1 Poisons 198
- VI. Suppression and/or Enhancement of Top1 Cleavage Complexes  
by DNA Damage 201
- VII. Processing of Top1-Mediated DNA Lesions 209
- VIII. Conclusions 211
- References 211

Index 217